Highlights on endoglin (CD105): From basic findings towards clinical applications in human cancer

Journal of Translational Medicine

Volumn 2, Issue , 2004, Pages

  Fonsatti, Ester ^a   Maio, Michele ^a,b  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; CELL MEMBRANE MARKER; CELL SURFACE PROTEIN; ENDOGLIN; INDIUM 111; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD105; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; BREAST ADENOCARCINOMA; CELL PROLIFERATION; DRUG HALF LIFE; DRUG SCREENING; ENDOTHELIUM CELL; HUMAN; MELANOMA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; TISSUE DISTRIBUTION; TOXICITY TESTING; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

EID: 4344652820     PISSN: 14795876     EISSN: None     Source Type: Journal    
DOI: 10.1186/1479-5876-2-18     Document Type: Review

References (85)

1. Smith MR: Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003, 22:7359-7368.
2. Ménard S, Pupa SM, Campiglio M, Tagliabue E: Biologic and therapeutic role of HER2 in cancer. Oncogene 2003, 22:6570-6578.
3. Green MC, Murray JL, Hortobagyi GN: Monoclonal antibody therapy for solid tumors. Cancer Treat Rev 2000, 26:269-286.
4. Brekken RA, Li C, Kumar S: Strategies for vascular targeting in tumors. Int J Cancer 2002, 100:123-130.
5. Thorpe PE: Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004, 10:415-427.
6. Haruta Y, Seon BK: Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. Proc Natl Acad Sci U S A 1986, 83:7898-7902.
7. Gougos A, Letarte M: Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol 1988, 141:1925-1933.
8. Gougos A, Letarte M: Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 1990, 265:8361-8364.
9. Bellón T, Corbi A, Lastres P, Calés C, Cebrian M, Vera S, Cheifetz S, Massagué J, Letarte M, Bernabéu C: Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol 1993, 23:2340-2345.
10. Lastres P, Martín-Perez J, Langa C, Bernabéu C: Phosphorylation of the human-transforming-growth-factor-β-binding protein endoglin. Biochem J 1994, 301:765-768.
11. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King SW, Letarte M, Vitetta ES, Thorpe PE: Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1995, 1:1623-1634.
12. Miller DW, Graulich W, Karges B, Stahl S, Ernst M, Ramaswamy A, Sedlacek HH, Müller R, Adamkiewicz J: Elevated expression of endoglin, a component of the TGF-β-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer 1999, 81:568-572.
13. Fonsatti E, Jekunen AP, Kairemo KJ, Coral S, Snellman M, Nicotra MR, Natali PG, Altomonte M, Maio M: Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res 2000, 6:2037-2043.
14. Graulich W, Nettelbeck DM, Fischer D, Kissel T, Muller R: Cell type specificity of the human endoglin promoter. Gene 1999, 227:55-62.
15. Botella LM, Sanchez-Elsner T, Sanz-Rodriguez F, Kojima S, Shimada J, Guerrero-Esteo M, Cooreman MP, Ratziu V, Langa C, Vary CP, Ramirez JR, Friedman S, Bernabeu C: Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood 2002, 100:4001-4010.
16. Wong SH, Hamel L, Chevalier S, Philip A: Endoglin expression on human microvascular endothelial cells association with betaglycan and formation of higher order complexes with TGF-beta signalling receptors. Eur J Biochem 2000, 267:5550-5560.
17. Wang JM, Kumar S, Pye D, van Agthoven AJ, Krupinski J, Hunter RD: A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int J Cancer 1993, 54:363-370.
18. Krupinski J, Kaluza J, Kumar P, Kumar S, Wang JM: Role of angiogenesis in patients with cerebral ischemic stroke. Stroke 1994, 25:1794-1798.
19. Schimming R, Marme D: Endoglin (CD105) expression in squamous cell carcinoma of the oral cavity. Head Neck 2002, 24:151-156.
20. Torsney E, Charlton R, Parums D, Collis M, Arthur HM: Inducible expression of human endoglin during inflammation and wound healing in vivo. Inflamm Res 2002, 51:464-470.
21. Chung YC, Hou YC, Pan AC: Endoglin (CD105) expression in the development of haemorrhoids. Eur J Clin Invest 2004, 34:107-112.
22. Fonsatti E, Del Vecchio L, Altomonte M, Sigalotti L, Nicotra MR, Coral S, Natali PG, Maio M: Endoglin: An accessory component of the TGF-beta- binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol 2001, 188:1-7.
23. Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M: Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene 2003, 22:6557-6563.
24. Wang JM, Kumar S, Pye D, Haboubi N, Al-Nakib L: Breast carcinoma: comparative study of tumor vasculature using two endothelial cell markers. J Natl Cancer Inst 1994, 86:386-388.
25. Wikstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A: Endoglin [CD105] is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 2002, 51:268-275.
26. Yu JX, Zhang XT, Liao YQ, Zhang QY, Chen H, Lin M, Kumar S: Relationship between expression of CD105 and growth factors in malignant tumors of gastrointestinal tract and its significance. World J Gastroenterol 2003, 9:2866-2869.
27. Cheifetz S, Bellón T, Calés C, Vera S, Bernabéu C, Massagué J, Letarte M: Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 1992, 267:19027-19030.
28. Lastres P, Letamendía A, Zhang H, Ríus C, Almendro N, Raab U, López LA, Langa C, Fabra A, Letarte M, Bernabéu C: Endoglin modulates cellular response to TGF-β1. J Cell Biol 1996, 133:1109-1121.
29. Barbara NP, Wrana JL, Letarte M: Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-β superfamily. J Biol Chem 1999, 274:584-594.
30. Govinden R, Bhoola KD: Genealogy, expression, and cellular function of transforming growth factor-beta. Pharmacol Ther 2003, 98:257-265.
31. Letamendía A, Lastres P, Botella LM, Raab U, Langa C, Velasco B, Attisano L, Bernabéu C: Role of endoglin in cellular responses to transforming growth factor-β. J Biol Chem 1998, 273:33011-33019.
32. Li C, Hampson IN, Hampson L, Kumar P, Bernabéu C, Kumar S: CD105 antagonizes the inhibitory signaling of transforming growth factor β1 on human vascular endothelial cells. FASEB J 2000, 14:55-64.
33. Ma X, Labinaz M, Goldstein J, Millere H, Keon WJ, Letarte M, O'Brien E: Endoglin is overexpressed after arterial injury and is required for transforming growth factor-β-induced inhibition of smooth muscle cell migration. Arterioscler Thromb Vasc Biol 2000, 20:2546-2552.
34. Diez-Marques L, Ortega-Velazquez R, Langa C, Rodriguez-Barbero A, Lopez-Novoa JM, Lamas S, Bernabeu C: Expression of endoglin in human mesangial cells: modulation of extracellular matrix synthesis. Biochim Biophys Acta 2002, 1587:36-44.
35. Guerrero-Esteo M, Sanchez-Elsner T, Letamendia A, Bernabeu C: Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. J Biol Chem 2002, 277:29197-29209.
36. Li C, Issa R, Kumar P, Hampson IN, Lopez-Novoa JM, Bernabeu C, Kumar S: CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci 2003, 116:2677-2685.
37. Guerrero-Esteo M, Lastres P, Letamendia A, Perez-Alvarez MJ, Langa C, Lopez LA, Fabra A, Garcia-Pardo A, Vera S, Letarte M, Bernabeu C: Endoglin overexpression modulates cellular morphology, migration, and adhesion of mouse fibroblasts. Eur J Cell Biol 1999, 78:614-623.
38. Botella LM, Sanz-Rodriguez F, Sanchez-Elsner T, Langa C, Ramirez JR, Vary C, Roughley PJ, Bernabeu C: Lumican is down-regulated in cells expressing endoglin. Evidence for an inverse correlationship between Endoglin and Lumican expression. Matrix Biol 2004, 22:561-572.
39. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabeu C: Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 2002, 277:43799-43808.
40. Ríus C, Smith JD, Almendro N, Langa C, Botella LM, Marchuk DA, Vary CPH, Bernabéu C: Cloning of the promoter region of human endoglin, the target gene for hereditary hemorrhagic telangiectasia type 1. Blood 1998, 92:4677-4690.
41. Zhu Y, Sun Y, Xie L, Jin K, Sheibani N, Greenberg DA: Hypoxic induction of endoglin via mitogen-activated protein kinases in mouse brain microvascular endothelial cells. Stroke 2003, 34:2483-8.
42. Li C, Guo B, Ding S, Rius C, Langa C, Kumar P, Bernabeu C, Kumar S: TNF alpha down-regulates CD105 expression in vascular endothelial cells: a comparative study with TGF beta 1. Anticancer Res 2003, 23:1189-1196.
43. Ota TM, Fujii M, Sugizaki T, Ishii M, Miyazawa K, Aburatani H, Miyazono K: Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells. J Cell Physiol 2002, 193:299-318.
44. Tanaka F, Ishikawa S, Yanagihara K, Miyahara R, Kawano Y, Li M, Otake Y, Wada H: Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res 2002, 62:7124-7129.
45. Duff SE, Li C, Garland JM, Kumar S: CD105 is important for angiogenesis: evidence and potential applications. FASEB J 2003, 17:984-992.
46. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, Boak BB, Wendel DP: Defective angiogenesis in mice lacking endoglin. Science 1999, 284:1534-1537.
47. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ: Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 1995, 121:1845-54.
48. Urness LD, Sorensen LK, Li DY: Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet 2000, 26:328-331.
49. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J, McCormick MK, Pericak-Vance MA, Heutink P, Oostra BA, Haitjema T, Westerman CJJ, Porteous ME, Guttmacher AE, Letarte M, Marchuk DA: Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994, 8:345-351.
50. Bourdeau A, Faughnan ME, McDonald ML, Paterson AD, Wanless IR, Letarte M: Potential role of modifier genes influencing transforming growth factor-beta1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia. Am J Pathol 2001, 158:2011-2020.
51. van den Driesche S, Mummery CL, Westermann CJ: Hereditary hemorrhagic telangiectasia: an update on transforming growth factor beta signaling in vasculogenesis and angiogenesis. Cardiovasc Res 2003, 58:20-31.
52. Jerkic M, Rivas-Elena JV, Prieto M, Carron R, Sanz-Rodriguez F, Perez-Barriocanal F, Rodriguez-Barbero A, Bernabeu C, Lopez-Novoa JM: Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J 2004, 18:609-611.
53. Akagi K, Ikeda Y, Sumiyoshi Y, Kimura Y, Kinoshita J, Miyazaki M, Abe T: Estimation of angiogenesis with anti-CD105 immunostaining in the process of colorectal cancer development. Surgery 2002, 131(1 Suppl):S109-113.
54. Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P, Taranger-Charpin C: Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression. Hum Pathol 2004, 35:176-183.
55. Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P, Taranger-Charpin C: Prediction of metastasis risk [11 year follow-up] using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer [n = 905]. Br J Cancer 2004, 90:1216-1221.
56. Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, Ishikawa S, Wada H: Correlation between apoptotic index and angiogenesis in non-small cell lung cancer: comparison between CD105 and CD34 as a marker of angiogenesis. Lung Cancer 2003, 39:289-296.
57. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
58. Maier JA, Delia D, Thorpe PE, Gasparini G: In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 [TNP-470] and the anti-endoglin antibody TEC-11. Anticancer Drugs 1997, 8:238-244.
59. She X, Matsuno F, Harada N, Tsai H, Seon BK: Synergy between anti-endoglin [CD105] monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells. Int J Cancer 2004, 108:251-257.
60. Nettelbeck DM, Miller DW, Jerome V, Zuzarte M, Watkins SJ, Hawkins RE, Muller R, Kontermann RE: Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin [CD105]. Mol Ther 2001, 3:882-891.
61. Velasco B, Ramirez JR, Relloso M, Li C, Kumar S, Lopez-Bote JP, Perez-Barriocanal F, Lopez-Novoa JM, Cowan PJ, d'Apice AJ, Bernabeu C: Vascular gene transfer driven by endoglin and ICAM-2 endothelial-specific promoters. Gene Ther 2001, 8:897-904.
62. Cowan PJ, Shinkel TA, Fisicaro N, Godwin JW, Bernabeu C, Almendro N, Rius C, Lonie AJ, Nottle MB, Wigley PL, Paizis K, Pearse MJ, d'Apice AJ: Targeting gene expression to endothelium in transgenic animals: a comparison of the human ICAM-2, PECAM-1 and endoglin promoters. Xenotransplantation 2003, 10:223-231.
63. Korn T, Muller R, Kontermann RE: Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes. J Immunother 2004, 27:99-106.
64. Savontaus MJ, Sauter BV, Huang TG, Woo SL: Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells. Gene Ther 2002, 9:972-979.
65. Bredow S, Lewin M, Hofmann B, Marecos E, Weissleder R: Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. Eur J Cancer 2000, 36:675-681.
66. Costello B, Li C, Duff S, Butterworth D, Khan A, Perkins M, Owens S, Al-Mowallad AF, O'Dwyer S, Kumar S: Perfusion of 99Tcm-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target. Int J Cancer 2004, 109:436-441.
67. Seon BK, Matsuno F, Haruta Y, Kondo M, Barcos M: Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 1997, 3:1031-1044.
68. Matsuno F, Haruta Y, Kondo M, Tsai H, Barcos M, Seon BK: Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res 1999, 5:371-382.
69. 125I-labeled anti-endoglin monoclonal antibodies. Int J Cancer 1999, 82:737-742.
70. Takahashi N, Haba A, Matsuno F, Seon BK: Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin [CD105] monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 2001, 61:7846-7854.
71. Griffioen AW, Damen CA, Blijham GH, Groenewegen G: Endoglin/CD105 may not be an optimal tumor endothelial treatment target. Breast Cancer Res Treat 1996, 39:239-242.
72. Balza E, Castellani P, Zijlstra A, Neri D, Zardi L, Siri A: Lack of specificity of endoglin expression for tumor blood vessels. Int J Cancer 2001, 94:579-585.
73. Seon BK: Expression of endoglin [CD105] in tumor blood vessels. Int J Cancer 2002, 99:310-311.
74. Grisanti S, Canbek S, Kaiserling E, Adam A, Lafaut B, Gelisken F, Szurman P, Henke-Fahle S, Oficjalska-Mlynczak J, Bartz-Schmidt KU: Expression of endoglin in choroidal neovascularization. Exp Eye Res 2004, 78:207-213.
75. Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM, Bundred N: Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 1999, 59:856-861.
76. Dales JP, Garcia S, Bonnier P, Duffaud F, Andrac-Meyer L, Ramuz O, Lavaut MN, Allasia C, Charpin C: CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients. Am J Clin Pathol 2003, 119:374-380.
77. Brewer CA, Setterdahl JJ, Li MJ, Johnston JM, Mann JL, McAsey ME: Endoglin expression as a measure of microvessel density in cervical cancer. Obstet Gynecol 2000, 96:224-228.
78. Li C, Gardy R, Seon BK, Duff SE, Abdalla S, Renehan A, O'Dwyer ST, Haboubi N, Kumar S: Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer 2003, 88:1424-1431.
79. Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF: Endoglin [CD105] and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol 2004, 17:197-203.
80. Salvesen HB, Gulluoglu MG, Stefansson I, Akslen LA: Significance of CD105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. APMIS 2003, 111:1011-1018.
81. Saad RS, Jasnosz KM, Tung MY, Silverman JF: Endoglin [CD105] expression in endometrial carcinoma. Int J Gynecol Pathol 2003, 22:248-253.
82. Straume O, Akslen LA: Expresson of vascular endothelial growth factor, its receptors [FLT-1, KDR] and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 2001, 159:223-235.
83. Adam M, Schmidt D, Wardelmann E, Wernert N, Albers P: Angiogenetic protooncogene ets-1 induced neovascularization is involved in the metastatic process of testicular germ cell tumors. Eur Urol 2003, 44:329-336.
84. Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, Yamada T, Hanaoka N, Inui K, Wada H: Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 2001, 7:3410-3415.
85. Yagasaki H, Kawata N, Takimoto Y, Nemoto N: Histopathological analysis of angiogenic factors in renal cell carcinoma. Int J Urol 2003, 10:220-227